GlassScriptPhysician profile
Scott R Capen
NPI 1386646925
$3,520.87
in general payments reported to CMS, 2019-2025
31 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $307 · 2021: $62.08 · 2022: $199 · 2023: $757 · 2024: $768 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.51 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Novo Nordisk INC | $418.67 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $397.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $237.95 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $234.99 | 2019-2025 | |
| Astellas Pharma US INC | $221.67 | 2019-2025 | Veozah |
| Lilly USA, LLC | $204.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Supernus Pharmaceuticals, INC. | $192.84 | 2019-2023 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $115.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $104.57 | 2020 | |
| Allergan, INC. | $102.20 | 2019-2020 | |
| Amgen INC. | $101.70 | 2022-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $80.12 | 2019-2025 | Trintellix |
| Corium, LLC | $61.29 | 2022-2025 | Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $34.86 | 2024-2025 | Rexulti |
| Abbott Laboratories | $34.67 | 2022-2025 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $32.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.78 | 2020 | |
| Averitas Pharma INC. | $18.37 | 2025 | Qutenza |
| Eisai INC. | $16.96 | 2024 | |
| Medtronic, INC. | $15.44 | 2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $15.17 | 2025 | Jornay Pm |
| Amneal Pharmaceuticals LLC | $15.16 | 2023 | Unithroid |
| Merck Sharp & Dohme LLC | $14.90 | 2023 | Dificid, Lagevrio |
| Seqirus USA INC | $14.75 | 2019 | |
| Lundbeck LLC | $14.28 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.34 | 2019 | |
| Mylan Specialty L.P. | $12.69 | 2020 | |
| Circassia INC. | $11.26 | 2019 | |
| Mayne Pharma Commercial LLC | $8.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Capen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.